Occlutech Holding AG

Occlutech is a leading specialist provider of minimally invasive cardiac implants for structural heart disease, founded in 2003 and headquartered in Sweden with manufacturing facilities in Germany and Turkey. The company designs, manufactures, and commercializes best-in-class cardiac devices addressing three primary therapeutic areas: congenital heart disease, stroke prevention and adult intervention, and heart failure management. With over 220,000 products implanted globally across more than 70 countries and a portfolio exceeding 200 patents, Occlutech serves an international network of healthcare professionals and distribution partners. Key products include occluders for atrial septal defects (ASD), patent foramen ovale (PFO), patent ductus arteriosus (PDA), ventricular septal defects (VSD), paravalvular leak closure, and left atrial appendage (LAA) closure devices. The company's flagship ASD Occluder received FDA approval in December 2023, marking its entry into the U.S. market. With approximately 330 employees, Occlutech combines clinical expertise with proprietary technology to deliver interventional solutions that improve quality of life for cardiac patients.